Lilly cancer drug cleared by FDA for expanded leukemia, lymphoma use

Jaypirca, which has been on the market for less than a year, can now be used for more types of blood cancer but not as early as rival drugs from AbbVie and AstraZeneca.

Related Keywords

Johnson Imbruvica ,Astrazeneca Calquence ,Roche Venclexta ,Eli Lilly ,Drug Administration ,Dive Brief ,Loxo Oncology ,Biopharma Dive ,Chronic Lymphocytic Leukemia ,Cancer Drugs ,Conditional Approval ,Lymphocytic Leukemia ,Food And Drug Administration ,Stk ,Oral Cancer ,Imbruvica ,Blood Cancer ,Leukemia ,Drugs ,